Reflection of successful anticancer drug development processes in the literature

Heinemann F, Huber T, Meisel C, Bundschus M, Leser U.

Drug Discov Today. 2016 Nov 16

PMID: 27443674 

http://www.ncbi.nlm.nih.gov/pubmed/27443674

Abstract

The development of cancer drugs is time-consuming and expensive. In particular, failures in late-stage clinical trials are a major cost driver for pharmaceutical companies. This puts a high demand on methods that provide insights into the success chances of new potential medicines. In this study, we systematically analyze publication patterns emerging along the drug discovery process of targeted cancer therapies, starting from basic research to drug approval - or failure. We find clear differences in the patterns of approved drugs compared with those that failed in Phase II/III. Feeding these features into a machine learning classifier allows us to predict the approval or failure of a targeted cancer drug significantly better than educated guessing. We believe that these findings could lead to novel measures for supporting decision making in drug development.